Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort

Thorax

Volumn 63, Issue 7, 2008, Pages 599-605

  Johnston, A K ^a   Mannino, D M ^a   Hagan, G W ^b   Davis, K J ^c   Kiri, V A ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOBAL INITIATIVE ON OBSTRUCTIVE LUNG DISEASE CRITERION; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

AGED; CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC METHODS; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; VITAL CAPACITY;

EID: 47049114097     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.088112     Document Type: Article

References (41)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
3. Burrows B. Predictors of loss of lung function and mortality in obstructive lung diseases. Eur Respir Rev 1991;1:340-5.
4. Gibbons L, Shapiro SH, Martin JG, et al. Predictors of mortality in severe chronic obstructive pulmonary-disease (COPD). Am J Epidemiol 1990;132:821.
5. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640-6.
6. Mannino DM, Doherty DE, Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006;100:115-22.
7. Mannino DM, Holguin F, Pavlin BI, et al. Risk factors for prevalence of and mortality related to restriction on spirometry: findings from the First National Health and Nutrition Examination Survey and follow-up. Int J Tuberc Lung Dis 2005;9:613-21.
8. Ryan G, Knuiman MW, Divitini ML, et al. Decline in lung function and mortality: the Busselton Health Study. J Epidemiol Community Health 1999;53:230-4.
9. Gulsvik A. The global burden and impact of chronic obstructive pulmonary disease worldwide. Monaldi Arch Chest Dis 2001;56:261-4.
10. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999;30:736-43.
11. Andreas S, Anker SD, Scanlon PD, et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 2005;128:3618-24.
12. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80.
13. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003;114:758-62.
14. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res 2006;7:70.
15. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-19.
16. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70.
17. Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998;279:119-24.
18. Hozawa A, Billings JL, Shahar E, et al. Lung function and ischemic stroke incidence: the Atherosclerosis Risk in Communities study. Chest 2006;130:1642-9.
19. Pistelli R, Lange P, Miller DL. Determinants of prognosis of COPD in the elderly: mucus hypersecretion, infections, cardiovascular comorbidity. Eur Respir J Suppl 2003;40:10s-14.
20. Schroeder EB, Welch VL, Couper D, et al. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2003;158:1171-81.
21. Schroeder EB, Welch VL, Evans GW, et al. Impaired lung function and subclinical atherosclerosis. The ARIC Study. Atherosclerosis 2005;180:367-73.
22. Zureik M, Kauffmann F, Touboul PJ, et al. Association between peak expiratory flow and the development of carotid atherosclerotic plaques. Arch Intern Med 2001;161:1669-76.
23. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068-75.
24. Pauwels RA, Buist AS, Calverley PM, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
25. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687- 702.
26. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995;152:1107-36.
27. American Thoracic Society. Standardization of Spirometry. Am Rev Respir Dis 1979;119:831-8.
28. Ferdinands JM, Mannino DM, Gwinn ML, et al. ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study. PLoS One 2007;2:e289.
29. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
30. Rautaharju PM, Calhoun HP, Chaitman BR. NOVACODE serial ECG classification system for clinical trials and epidemiologic studies. J Electrocardiol 1992;24(Suppl):179-87.
31. Kors JA, Crow RS, Hannan PJ, et al. Comparison of computer-assigned Minnesota Codes with the visual standard method for new coronary heart disease events. Am J Epidemiol 2000;151:790-7.
32. Machado DB, Crow RS, Boland LL, et al. Electrocardiographic findings and incident coronary heart disease among participants in the Atherosclerosis Risk in Communities (ARIC) study. Am J Cardiol 2006;97:1176-81.
33. Rathore SS, Hinn AR, Cooper LS, et al. Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study. Stroke 2002;33:2718-21.
34. Howard G, Manolio TA, Burke GL, et al. Does the association of risk factors and atherosclerosis change with age? An analysis of the combined ARIC and CHS cohorts. The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Study (CHS) investigators. Stroke 1997;28:1693-701.
35. Huiart L, Ernst P, Ranouil X, et al. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005;25:634-9.
36. Huiart L, Ernst P, Ranouil X, et al. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Can Respir J 2006;13:134-8.
37. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-60.
38. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
39. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
40. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-7.
41. Onufrak S, Abramson J, Vaccarino V. Adult-onset asthma is associated with increased carotid atherosclerosis among women in the atherosclerosis risk in communities (ARIC) study. Atherosclerosis 2007;195:129-37.